全通教育(300359.SZ)擬定增募資不超2億元 由控股股東認購
格隆匯2月28日丨全通教育(300359.SZ)發佈2022年度向特定對象發行股票預案,擬向特定對象發行的股票數量不超過4175.3653萬股(含本數),按照此次向特定對象發行募集資金總額除以最終發行價格計算得出,且不超過此次發行前公司總股本的30%,最終發行數量由董事會根據股東大會的授權、深交所、中國證監會相關規定與保薦機構(主承銷商)協商確定。
發行對象為公司控股股東南昌經濟技術開發區中文旭順企業管理合夥企業(有限合夥),發行價為4.79元/股,募集資金總額不超2億元(含本數),募集資金在扣除發行費用後計劃全部用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.